NCT02218125View on ClinicalTrials.gov

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 23, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Healthy
Interventions
BIOLOGICAL

MVA Mosaic

0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.

BIOLOGICAL

Placebo

0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.

Trial Locations (1)

Unknown

Boston

All Listed Sponsors
collaborator

US Military HIV Research Program

NETWORK

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Crucell Holland BV

INDUSTRY

NCT02218125 - A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults | Biotech Hunter | Biotech Hunter